Development of anti-Alzheimer's drugs and their molecular targets

Toshitaka Nabeshima, Kiyofumi Yamada

Research output: Contribution to journalArticle

Abstract

Alzheimer's disease (AD) is a neurodegenerative disorder that is neuropathologically characterized by the presence of numerous senile plaques and neurofibrillaiy tangles accompanied by neuronal loss. The extracellular senile plaques are composed of amyloid β-peptides (Aβ), 40-42 amino acid peptide fragments of the β-amyloid precursor protein (APP), whereas the intracellular neurofibrillaiy tangles are composed of highly phosphorylated tau proteins. Some forms of familial AD are caused by the inheritance of mutant genes, including genes encoding the amyloid precursor protein (APP) and presenilin 1 (PS1) and 2 (PS2). There is also an association between AD and apolipoprotein E (ApoE) gene. Although the exact pathogenesis of AD remains to be fully defined, several pharmacological strategies for the treatment of AD are under active investigation. These include the cholinergic therapy that is designed to increase cholinergic functions, anti-inflammatory agents and antioxidants. The anti-Aβ strategies in AD, which refer to intervention of the amyloid cascade of the disease, are the most attractive approaches for the treatment of AD. Other possible strategies involve vaccine therapy with Aβ immunization and neurotrophic factor therapy.

Original languageEnglish
JournalFolia Pharmacologica Japonica
Volume118
Issue numberSUPPL. 1
Publication statusPublished - 01-12-2001
Externally publishedYes

Fingerprint

Alzheimer Disease
Pharmaceutical Preparations
Amyloid beta-Protein Precursor
Amyloid Plaques
Amyloid
Cholinergic Agents
Presenilin-2
Genes
Presenilin-1
Active Immunotherapy
tau Proteins
Peptide Fragments
Nerve Growth Factors
Apolipoproteins E
Therapeutics
Neurodegenerative Diseases
Immunization
Anti-Inflammatory Agents
Antioxidants
Pharmacology

All Science Journal Classification (ASJC) codes

  • Pharmacology

Cite this

@article{145ad67e4ab04991b8be4718dd4ec107,
title = "Development of anti-Alzheimer's drugs and their molecular targets",
abstract = "Alzheimer's disease (AD) is a neurodegenerative disorder that is neuropathologically characterized by the presence of numerous senile plaques and neurofibrillaiy tangles accompanied by neuronal loss. The extracellular senile plaques are composed of amyloid β-peptides (Aβ), 40-42 amino acid peptide fragments of the β-amyloid precursor protein (APP), whereas the intracellular neurofibrillaiy tangles are composed of highly phosphorylated tau proteins. Some forms of familial AD are caused by the inheritance of mutant genes, including genes encoding the amyloid precursor protein (APP) and presenilin 1 (PS1) and 2 (PS2). There is also an association between AD and apolipoprotein E (ApoE) gene. Although the exact pathogenesis of AD remains to be fully defined, several pharmacological strategies for the treatment of AD are under active investigation. These include the cholinergic therapy that is designed to increase cholinergic functions, anti-inflammatory agents and antioxidants. The anti-Aβ strategies in AD, which refer to intervention of the amyloid cascade of the disease, are the most attractive approaches for the treatment of AD. Other possible strategies involve vaccine therapy with Aβ immunization and neurotrophic factor therapy.",
author = "Toshitaka Nabeshima and Kiyofumi Yamada",
year = "2001",
month = "12",
day = "1",
language = "English",
volume = "118",
journal = "Folia Pharmacologica Japonica",
issn = "0015-5691",
publisher = "Japanese Pharmacological Society",
number = "SUPPL. 1",

}

Development of anti-Alzheimer's drugs and their molecular targets. / Nabeshima, Toshitaka; Yamada, Kiyofumi.

In: Folia Pharmacologica Japonica, Vol. 118, No. SUPPL. 1, 01.12.2001.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Development of anti-Alzheimer's drugs and their molecular targets

AU - Nabeshima, Toshitaka

AU - Yamada, Kiyofumi

PY - 2001/12/1

Y1 - 2001/12/1

N2 - Alzheimer's disease (AD) is a neurodegenerative disorder that is neuropathologically characterized by the presence of numerous senile plaques and neurofibrillaiy tangles accompanied by neuronal loss. The extracellular senile plaques are composed of amyloid β-peptides (Aβ), 40-42 amino acid peptide fragments of the β-amyloid precursor protein (APP), whereas the intracellular neurofibrillaiy tangles are composed of highly phosphorylated tau proteins. Some forms of familial AD are caused by the inheritance of mutant genes, including genes encoding the amyloid precursor protein (APP) and presenilin 1 (PS1) and 2 (PS2). There is also an association between AD and apolipoprotein E (ApoE) gene. Although the exact pathogenesis of AD remains to be fully defined, several pharmacological strategies for the treatment of AD are under active investigation. These include the cholinergic therapy that is designed to increase cholinergic functions, anti-inflammatory agents and antioxidants. The anti-Aβ strategies in AD, which refer to intervention of the amyloid cascade of the disease, are the most attractive approaches for the treatment of AD. Other possible strategies involve vaccine therapy with Aβ immunization and neurotrophic factor therapy.

AB - Alzheimer's disease (AD) is a neurodegenerative disorder that is neuropathologically characterized by the presence of numerous senile plaques and neurofibrillaiy tangles accompanied by neuronal loss. The extracellular senile plaques are composed of amyloid β-peptides (Aβ), 40-42 amino acid peptide fragments of the β-amyloid precursor protein (APP), whereas the intracellular neurofibrillaiy tangles are composed of highly phosphorylated tau proteins. Some forms of familial AD are caused by the inheritance of mutant genes, including genes encoding the amyloid precursor protein (APP) and presenilin 1 (PS1) and 2 (PS2). There is also an association between AD and apolipoprotein E (ApoE) gene. Although the exact pathogenesis of AD remains to be fully defined, several pharmacological strategies for the treatment of AD are under active investigation. These include the cholinergic therapy that is designed to increase cholinergic functions, anti-inflammatory agents and antioxidants. The anti-Aβ strategies in AD, which refer to intervention of the amyloid cascade of the disease, are the most attractive approaches for the treatment of AD. Other possible strategies involve vaccine therapy with Aβ immunization and neurotrophic factor therapy.

UR - http://www.scopus.com/inward/record.url?scp=18744397613&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=18744397613&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:18744397613

VL - 118

JO - Folia Pharmacologica Japonica

JF - Folia Pharmacologica Japonica

SN - 0015-5691

IS - SUPPL. 1

ER -